Netherlands· NL-5fe6a7465575
Pravafenix 40 mg/160 mg harde capsules
A pravastatin und fenofibrat product containing fenofibraat + pravastatine natrium, registered in Netherlands by Laboratoires S.M.B. S.A.. The same ATC class is registered in 8 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Pravastatin und fenofibrat is registered in 8 of 19 countries.
Countries holding a registration under ATC C10BA03 (pravastatin und fenofibrat), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 5 of them publish a price we can compare per daily dose
Pravastatin und fenofibrat · ATC C10BA03
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- FENOFIBRAAT + PRAVASTATINE NATRIUM
- Manufacturer
- Laboratoires S.M.B. S.A.
- Country
- Netherlands (NL)
- ATC code
- C10BA03
- ATC class
- Pravastatin und Fenofibrat
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/11/697
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pravastatin und fenofibrat in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPRAVAFENIXLaboratoires S.M.B. S.A., Brusel
- SpainPRAVAFENIX 40 mg/160 mg CAPSULAS DURASLaboratoires S.M.B. S.A.
- FinlandPravafenixLaboratoires SMB S.A.
- IrelandPravafenix 40 mg/160 mg hard capsulesLaboratoires SMB S.A.
- IcelandPravafenixLaboratoires SMB S.A.*
- PolandPravafenixLaboratoires SMB s.a.
- SwedenPravafenix 40 mg/160 mg Kapsel, hårdLaboratoires SMB S.A.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Spain · Pravastatina/Fenofibrato Cinfa
- Iceland · Pravafenix
- Liechtenstein · Pravafenix
- Norway · Pravafenix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/799a48a6-63d3-49a9-81cc-29e1c9144e73 GET /v1/drugs/799a48a6-63d3-49a9-81cc-29e1c9144e73?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/pravafenix-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Pravastatin and fenofibrate",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp106524",
"excipients": [
"ASCORBYLPALMITAAT (E 304)",
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"GELATINE (E 441)",
"GLYCEROLTRIACETAAT (E 1518)",
"HYPROLOSE (E 463)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ZWART (E 172)",
"INDIGOKARMIJN (E 132)",
"LACTOSE 1-WATER",
"LAUROYLMACROGOLGLYCERIDEN",
"MACROGOL 20000",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMWATERSTOFCARBONAAT (E 500 (II))",
"NATRIUMZETMEELGLYCOLAAT",
"POVIDON K 30 (E 1201)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"FENOFIBRAAT",
"PRAVASTATINE NATRIUM"
],
"leaflet_url": null,
"authorised_at": "2011/04/14",
"procedure_number": "EMEA/H/C/001243",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/11/697",
"additional_monitoring": "N"
}See everything about pravastatin und fenofibrat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.